NCT04072042View on ClinicalTrials.gov

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

October 30, 2026

Study Completion Date

September 1, 2027

Conditions
Sarcoma
Interventions
DRUG

Apatinib monotherapy

patients will receive Apatinib 250mg tablet by mouth, bid.

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER